The optimum choice of MRB and its dose, however, remain uncertain given the potential risk of hyperkalemia in patients with CKD. Edwards et al. evaluated spironolactone 25 mg per day—the lowest ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The ...

The trial aims to determine the effects of aldosterone receptor antagonism on mortality and cardiovascular outcomes (onset or progression of cardiovascular disease) in patients with stage 3b CKD ...

and CKD. What is not widely appreciated is Laragh's important contribution to delineating the pathophysiologic role aldosterone plays in the mediation of CV disease. Indeed, his research career ...

Renal hypoperfusion occurs as a result of reduced cardiac output, resulting in the activation of the renin–angiotensin–aldosterone system, which compensates for the hypoperfusion. However ...

Excessive aldosterone levels are suspected of causing organ damage and promote conditions such as high blood pressure, CKD, and heart failure. With the new data in hand, Boehringer said it now ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New ...

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone.

(Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, ...